





# **MCTPS: a new Monte Carlo**based treatment planning tool for hadrontherapy fondazioneCNAQ

MedAustron



G. Battistoni<sup>1</sup>, T.T. Böhlen<sup>2</sup>, A. Ferrari<sup>3</sup>, A. Mairani<sup>4</sup>, K. Parodi<sup>5</sup>, V. Patera<sup>6.7</sup>, A. Schiavi<sup>7</sup>

<sup>1</sup>INFN Sezione di Milano, Milan, Italy, <sup>2</sup>Medaustron, Austria, <sup>3</sup>CERN, Switzerland, <sup>4</sup>CNAO, Pavia, Italy, <sup>5</sup>Ludwig Maximilian Univ., Munich & Uniklinikum Heidelberg, Germany <sup>6</sup>La Sapienza Università di Roma, Rome, Italy, <sup>7</sup>INFN Sezione di Roma1, Roma, Italy



#### A Monte Carlo based Treatment planning?

- Currently treatment planning for hadron therapy are commonly based on fast analytic dose engines using Pencil Beam algorithms.
- MC calculation of doses and fluences could be superior in accuracy <u>because they take into account</u> <u>heterogeneities</u>, large densities, geometry details.
   They can predict secondary particle production to be used for imaging, range control, etc.
- However they require much longer execution times...

#### **Project:** an integrated MC+optimization tool

- To take into account all details about geometry and materials, overcoming the "water-equivalent" approach
- Tool to be applied to realistic treatment conditions with acceptable CPU time
- That can be applied in planning for ions with 1<Z<8 (at CNAO and HIT)
- A tool which not only allows to recheck a given plan, but which also suggests a better solution
- To be used stand-alone (using some pre-processing code) or as post re-optimization of plans obtained from commercial TPS (here examples as applied at CNAO and HIT)
- To be used in research: New ions and combined ion fields, testing of new bio-models and algorithms, to predict secondary fluxes: β<sup>+</sup> emitters, prompt γ, etc.

# **Basic principles of MCTPS**

#### Multistep procedure:

- 1. start from a given set of PBs  $P_1(N_1)$  with pre-optimized initial particle numbers N<sub>1</sub>
- 2. This set can be obtained from a pre-selection and preoptimization of available PBs deliverable by the "accelerator beam library": Po for a given treatment and beam port:

- Two alternatives: an already available certified TPS - a fast simulator
- 3. Starting from  $P_1(N_1)$  the MC allows to calculate a Dose Kernel  $(D_{MC})$  using the <u>fully detailed case geometry</u>, composition and machine setting
- 4. An optimization code will derive iteratively from  $D_{MC}$  the optimized solution  $P_2(N_2)$

## **Components and program flow**



pencil beams

#### **D**<sub>MC</sub> : MC dose kernel

#### **Choice of the MC code**

**FLUKA** (INFN-CERN property) is the baseline choice for this project

(http://www.fluka.org)

- Presently used in hadron therapy context
- Includes sound physical models
- Capability of being coupled to CT scans to import geometry, to import volume/organ definitions
- Possibility to be coupled to a radiobiological model



See talk at this conference by P.R. Sala

# **Optimization procedure**

 $D_j(\mathbf{N}) = \sum_{i \in \mathbf{PB}} d_{i,j} \cdot N_i$  Absorbed dose in voxel j from PBs (running on i index)

**N** has to be determined by minimizing the following cost function:

$$\chi^{2}(\mathbf{N}) = \sum_{j \in \text{PTV}} \frac{w_{j}(\hat{D}_{j} - D_{j})^{2}}{\hat{D}_{j}^{2}} + \sum_{j \in \text{OAR}} \frac{w_{j}(\hat{D}_{j} - D_{j})^{2}}{\hat{D}_{j}^{2}} \Theta(\hat{D}_{j} - D_{j}).$$

Prescribed dose in dose grid voxel

Weight associated to grid voxel j based on planner's prescription

D<sub>RBE,j</sub> can replace D<sub>j</sub> Two optimization methods tested:

1) Gradient-Based optimization ("Steepest Descent")

2) "Dose-Difference Optimization" approach described in Lomax, PMB 44 (1999) 185

#### **Calculation choices**

- In order to compare to standard TP calculation Dose has to be expressed as Dose-To-Water. TP rescale depth-dose profiles in water using Water Equivalent Path Length (WEPL) approximantion. In MC we can score Dose-To-Water as derived directly from Dose-To-Medium.
- RBE alternatives:
  - fixed (fort instance ~ 1.1 for protons)
  - Radiobiological input tables computed with LEM are interfaced with FLUKA to calculate RBE-weighted doses D<sub>RBE</sub>
  - Values of non-constant RBE are obtained by a re-implementation of the "local effect model" (LEM, version IV) developed in Heidelberg *Elsasser T. et al., Int. J. Radiat. Oncol. 78 (2010) 1177-1184*

Warning: using for the moment a the reference V79 cell line (non-human) typical in radiobiology studies

#### Verification of MCTPS Plans. Protons at CNAO

#### • Cases:

- Phantoms for which we used as pre-optimizer Syngo RT Planning by Siemens AG (CNAO standard) and alternatively, a fast MC skimmer (FRED, by A. Schiavi)
- Patient caes at CNAO with 2 or 3 beam ports for protons. D=2 Gy for PTV either with fixed RBE=1.1 or variable RBE as predicted by LEM. PTVs of 32.5 ml and 103.5 ml. Pre-optimizier: the Syngo TPS

# **MC Set-up**

- Simulation set up includes CNAO Nozzle so to generate "PB" with actual phase space distribution: lateral FWHM ~ 1.0 cm at isocenter, lateral spacing of 3 mm. Spacing between Bragg peak position of 2 neighbouring beam energies 2 mm.
- Simulation includes voxelized water phantom or CT patient image: 2x2 mm<sup>2</sup> transaxial pixels and 2 mm slices (as for the certified default TPS at CNAO). This defines transport and scoring granularity in MC
- Materials and Composition (see talk about FLUKA) assigned to voxels according to Schneider et al, PMB 45 (2000) 459 and Parodi et al. PMB 52 (2007) 3369
- In order to build the Dose Kernel Matrix  $D_{MC} \equiv (d_{j,i}; a_{j,i}; b_{j,i})$  a total no. of PB to be simulated: 3438 for the cube-shaped PTV to 6257 and 13920 for the 2 patient cases
- 5 10<sup>3</sup> primary protons per PB at the given granularity 
   → mean statistical uncertainty on PTV ~ 1% (max 2%)

# A 3-port chordoma case treated with protons at CNAO



## **DVHs for PTV and OAR**



#### 2-port

3-port

By comparing MCTPS with MC fw simulation of TPS prescription:

The % of volume fulfilling gamma index criterion for PTV is 91% and 81% for OAR

The % of volume fulfilling gamma index criterion for PTV is 72% and 90% for OAR

# RBE as predicted by LEM for abs. doses larger than 10% of prescribed dose



#### **3-port case**



RBE as predicted by LEM for abs. doses larger than 10% of prescribed dose





#### A Carbon Case study

#### **MCTPS implemented @HIT**



Boehlen TT, et al. Journal of Radiation Research 54, i77-i81 (2013)



# **Computing effort**

Example: for the 2-port patient case:

```
MC calc. of RBE-weighted dose matrixes (5 k MC histories per PB) =
50 h (20 CPUs, 10 CPUs/field
```

```
Optimization time = 2h(1 \text{ CPU})
```

```
52 hours
```

```
A local cluster ~100 cores would be recommended
```

Essential a development of accelerating techniques in MC calculation

Simulation speed-up in FLUKA: see POSTER by C. Mancini et al

Cloud approach: the cost of 1000 hour of CPU can be estimated around 100 Euros (no prioritary service)

### A new case: exploring use of He ions

- Very preliminary results.
- RBE fixed ~1.3 (*A. Brahme 2004*) as a starting point. In future variable RBE
- The nuclear model of FLUKA for He interactions is in development: ~good for E≤100 MeV/u (BME); to be improved for 100<E<few 1000 MeV/nucleon(RQMD)</li>
- No clinically oriented study yet
- The study is aimed:
  - to show capabilities of MCTPS
  - to study Multiple Coulomb Scattering effects on dose distribution comparison between <sup>4</sup>He and <sup>1</sup>H

### A new case: exploring use of He ions



### A new case: exploring use of He ions



# Some Conclusions about the MCTPS

- The achieved results are very promising
- Computation speed is actually acceptable only for a research tool, for the moment

#### In progress:

- Study robustness of MCTPS plans
- Integrate the different pieces together including graphical tools

#### Acknowlegments

- CNAO Medical Division
- HIT Medical Physics Research Group
- ENVISION EU-FP7 project